



Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

October 15, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 15, 2026-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026.

An archived copy of the webcast will be available on the [events](#) section of the Company's website for approximately 90 days following the live presentation.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Spruce's lead product candidate, traleseninidase alfa enzyme replacement therapy (TA-ERT), is in late-stage development for the treatment of MPS IIIB, a devastating pediatric neurodegenerative disorder for which there are no FDA-approved therapies. TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union. To learn more, visit www.sprucebio.com and follow us on [X](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20261015117605/en/>

Media

Heidi Chokeir
Inizio Evoke Comms
Heidi.Chokeir@inizioevoke.com
media@sprucebio.com

Investors

Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
investors@sprucebio.com

Source: Spruce Biosciences, Inc.